CorMedix reaffirms revenue guidance, reports cash position
CorMedix Inc. announces strong cash position and reaffirms revenue guidance for 2026, impacting the pharmaceutical preparations industry.
PLDT Inc. changes external auditor amid governance shift
PLDT Inc. announces a change in its external auditor, reflecting a shift in governance practices that may influence the telecommunications industry.
Loews Corp Reports Third-Quarter Earnings Results
Loews Corp's third-quarter earnings reflect stability in the insurance sector, impacting investor confidence and industry trends.
Oracle Corp Files Registration Statement for Securities Offering
Oracle Corp has filed a registration statement to offer various securities, signaling a strategic move to raise capital and enhance its market position.
LS Power Proposes $2 Per Share Acquisition of EVgo Inc.
LS Power Equity Advisors proposes to acquire all outstanding shares of EVgo Inc. for $2 each, signaling potential changes in the automotive services sector.
Tidal Trust II files summary prospectus for new ETF
Tidal Trust II files a summary prospectus for its XFUNDS™ Value Income ETF, focusing on capital appreciation and current income through diversified investment strategies.
Cadeler plc Amends Tender Offer, Accepts 355 Million Shares
Cadeler plc amends its tender offer, accepting over 355 million shares from Cadeler A/S, marking a significant shift in ownership and operations.
Lightbridge Corp announces third quarter results and updates
Lightbridge Corp reports Q3 results, showcasing advancements in nuclear fuel technology and financial growth, impacting the industrial inorganic chemicals sector.
Tower Semiconductor Reports Record Q3 Results, Strong Outlook
Tower Semiconductor announces record Q3 2026 results with $526 million in revenue, projecting continued growth into Q4, indicating strong industry performance.
Kaiser Yaron Boosts Stake in Steakholder Foods Ltd.
Kaiser Yaron increases his stake in Steakholder Foods Ltd. with recent share purchases, reflecting confidence in the company's future in food manufacturing.
Voya Credit Income Fund Announces Monthly Share Repurchase Offer
Voya Credit Income Fund announces a monthly share repurchase offer starting November 6, 2026, providing liquidity to shareholders.
Brainsway Announces Strategic Collaboration with Mindful Health Solutions
Brainsway Ltd. partners with Mindful Health Solutions to enhance access to noninvasive mental health treatments, signaling a shift in the surgical and medical instruments industry.
Warberg Asset Management Reports $755 Million in Holdings
Warberg Asset Management LLC's latest 13F-HR reveals $755 million in investments, showcasing its commitment to transparency in asset management.
Delos Meridian Corp. files new offering for $500,000
Delos Meridian Corp. seeks to raise $500,000 through a SAFE note, aiming to fund operations and cover executive salaries.
Franklin California Tax Free Trust Updates Fund Prospectus
Franklin California Tax Free Trust files new summary prospectus for its Intermediate-Term Tax-Free Income Fund, effective November 1, 2026.
Pasqal Holding SA Registers Shares for Employee Incentive Plans
Pasqal Holding SA has filed a registration statement for shares under employee incentive plans, enhancing its commitment to workforce engagement.
TAT Technologies Reports Record Q3 Results and Growth Plans
TAT Technologies Ltd. announces record revenue and profitability for Q3 2026, highlighting growth strategies in the aircraft engines sector.
Inovio Pharmaceuticals secures FDA approval for VOCERYQ
Inovio Pharmaceuticals has received FDA accelerated approval for VOCERYQ, an immunotherapy for adults with Recurrent Respiratory Papillomatosis, set for launch in early 2027.
Xcel Energy proposes $2 billion convertible notes offering
Xcel Energy Inc. announces a proposed offering of $2 billion in convertible senior notes due 2027, aiming to refinance debt and support corporate initiatives.
uniQure's ifezuntirgene inilparvovec BLA Accepted by FDA
uniQure N.V. announces FDA acceptance of its BLA for ifezuntirgene inilparvovec, a potential treatment for Huntington's disease, with a target action date of May 1, 2027.